Ultrasound-guided prolotherapy alleviates pain in patients with chronic tendinosis of the Achilles tendon, according to University of British Columbia researchers.
Ultrasound-guided prolotherapy alleviates pain in patients with chronic tendinosis of the Achilles tendon, according to University of British Columbia researchers.
Prolotherapy, developed in the late 1930s, consists of injecting an irritant solution into damaged ligaments or tendons to stimulate their healing. It has been described more recently in the clinical literature for the management of pain in conditions such as chronic tendinosis of the Achilles tendon.
Standard treatment involves dextrose injections at several sites around the tendon. The procedure is rarely completed with image guidance.
Dr. Norman J. Maxwell and colleagues tested two novel variations to the technique. Dextrose was injected through the tendon tissue rather than around, and ultrasound was employed to guide the procedure.
"We performed this treatment using a small needle under ultrasound guidance so that the abnormal areas could be accurately targeted," said Maxwell, a radiologist at the University of Pittsburgh Medical Center.
Results were published online in the October issue of the American Journal of Roentgenology (2007;189[4]:W215-220).
Maxwell and colleagues prospectively enrolled 36 consecutive patients whose conservative treatment for chronic tendinosis of the Achilles tendon had failed. Patients underwent ultrasound-guided intravenous injection of a hyperosmolar dextrose solution every six weeks until symptoms improved or the treatment proved unsuccessful.
The investigators assessed pain at rest, during normal motion, and during the practice of sport or other physically demanding activity using a visual test. They also recorded sonographic parameters such as tendon thickness, echogenicity, and neovascularity.
They found the ultrasound-guided therapy provided a significant reduction in pain for these patients while at rest and during tendon-loading activities. Thirty-three tendons in 32 patients were successfully treated in an average of four sessions. The mean reduction of pain at rest and during normal and enhanced activity was, respectively, 88.2% (p<0.0001), 84.0% (p<0.0001), and 78.1% (p<0.0001). Mean tendon thickness decreased from 11.7 mm to 11.1 mm (p<0.007). Anechoic foci decreased by 78% post-treatment. Echogenicity improved in six tendons but was unchanged in 27.
Neovascularity remained unchanged in 11 tendons but decreased in 18. No neovascularity was present before or after treatment in the four remaining tendons. Twenty of 30 patients available for follow-up one year after treatment were still asymptomatic, while the remaining 10 had only mild or moderate symptoms.
The presence of calcifications apparently influenced treatment outcomes, Maxwell said. Patients without tendon calcifications seemed to respond better to treatment than did patients who had calcifications.
"Despite these very encouraging results, further studies are required to validate the effectiveness of this treatment," Maxwell said.
For more information from the Diagnostic Imaging archives:
Ultrasound strums familiar chords in RSNA exhibits
As climging popularity soars, so do musculoskeletal injuries
MSK interventions open burgeoning new field
Ultrasound-guided therapy from U.K. intrigues North American interventionalists
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.